The companies may also target diseases such as amyotrophic lateral sclerosis, also known as Lou Gehrig's disease, Crooke and Scangos said. Biogen had been developing a drug for ALS, dexpramipexole, that failed to show any benefit earlier this year in the last stage of clinical trials."Biogen has a pretty aggressive program to understand more about the genetic causes of ALS," Scangos said. One part of that, an academic group, is "already generating interesting insights into the biology and some potential targets we would hope to be able to take forward."
The partnership is the first for Isis around an entire therapeutic area, Crooke said. The company doesn't have a sales force, preferring to make partnerships with larger drugmakers to run late-stage clinical studies and to market its medicines. Its first approved drug, Kynamro, for a rare cholesterol disorder, is marketed by Sanofi (SAN)'s Genzyme unit."This is the next step in the evolution of our partnering strategy," Crooke said. "It makes a lot of sense for us; what we need is to make sure our partners understand our technology, are ready for the drugs when they're ready for them, and that there are people in the organizations we can trust to do a good job with our assets."
Samuel Adams beer creator Jim Koch has reportedly become a billionaire, as sales of the popular beer have helpe Boston Beer Co. shares double in the past year. According to Bloomberg, shares of the company reached a record high on Friday, while overall beer sales have become stale.Sam Adams is one of the bright spots of the U.S. beer market. Reports said total American beer sales fell 2 percent in the first half of 2013, while the craft brew segment grew 15 percent. Boston Beer's sales increased more than 17 percent during the same period.
This is my favorite article:Stricter visa rules driving away medical tourism from India
No comments:
Post a Comment